US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

413.68

+18.254.62%

Number of Gainers:4

Number of Losers:2

Number of Flat:- -

PE:- -

High:418.89

Open:394.14

Low:387.79

Close:395.43

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)

Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)

Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations

Intellia Therapeutics Delivers a Q4 Beat

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

MT Newswires Live

Intellia Therapeutics Q4 Net Income USD -128.898 Million

Intellia Therapeutics Q4 Basic EPS USD -1.27

THOMSON REUTERS

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Beam Therapeutics Is Maintained at Sector Perform by RBC Capital

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Beam Therapeutics: Anticipated Growth Driven by BEAM-302 and SCD Franchise Progress

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS) and Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) Gets a Hold from Barclays

Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23

THOMSON REUTERS

Beam Therapeutics Reports 2024 Financial Results and Progress

Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4556/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":413.68384,"timestamp":1741381199999,"preClose":395.43274,"halted":0,"volume":13723847,"delay":0,"changeRate":0.046155,"change":18.251099,"pbRate":1.9827,"amount":163649532.723433,"amplitude":0.078654,"prevYearClose":376.62552,"fiveDayClose":396.1103,"twentyDayClose":388.3015,"turnoverRate":0.025125,"marketCap":7685371892,"floatMarketCap":7202041036,"peRate":-3.812751},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":418.8933,"amplitude":0.078654,"preClose":395.43274,"low":387.79083,"pbRate":"1.9827","latestPrice":413.68384,"volume":13723847,"delay":0,"open":394.13995,"prevYearClose":376.62552,"prevWeekClose":413.6838,"prevMonthClose":396.1103,"prevQuarterClose":376.6255,"fiveDayClose":396.1103,"twentyDayClose":388.3015,"sixtyDayClose":415.7698,"secType":"PLATE","market":"US","turnoverRate":0.025125,"peRate":-3.812751,"marketCap":7685371892,"floatMarketCap":7202041036,"timestamp":1741381199999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":4,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514316337","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514316337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514316337?lang=en_us&edition=fundamental","pubTime":"2025-02-28 04:30","pubTimestamp":1740688204,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intellia Therapeutics (NTLA – Research Report) and Cullinan Manag...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-intellia-therapeutics-ntla-and-cullinan-management-cgem?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-intellia-therapeutics-ntla-and-cullinan-management-cgem?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","LU1861558580.USD","BK4535","HCSG","BK4588","BK4137","BK4139","BK4556","NTLA","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2514780334","title":"Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780334?lang=en_us&edition=fundamental","pubTime":"2025-02-28 04:00","pubTimestamp":1740686416,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ironwood Pharma (IRWD – Research Report) and Intelli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ironwood-pharma-irwd-and-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ironwood-pharma-irwd-and-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","LU1861559042.SGD","IRWD","BK4535","LU1861558580.USD","NTLA","HCSG","BK4556","BK4585","BK4137"],"gpt_icon":0},{"id":"2514800573","title":"Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514800573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514800573?lang=en_us&edition=fundamental","pubTime":"2025-02-28 00:45","pubTimestamp":1740674715,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their neutral stance on BEAM stock, giving a Hold rating yesterday. Soumit Roy has given his Hold ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-optimism-for-beam-therapeutics-amid-upcoming-milestones-and-financial-considerations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-optimism-for-beam-therapeutics-amid-upcoming-milestones-and-financial-considerations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LENZ","BK4139","BK4588","BEAM","BK4535","BK4556","BK4585"],"gpt_icon":0},{"id":"2514838714","title":"Intellia Therapeutics Delivers a Q4 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2514838714","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514838714?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:35","pubTimestamp":1740670500,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2025/02/27/intellia-therapeutics-surges-in-revenue/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4556","LU1861559042.SGD","BK4139","BK4585","BK4535","BK4588","LU1861558580.USD","NTLA"],"gpt_icon":0},{"id":"2514388006","title":"Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388006","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388006?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:22","pubTimestamp":1740666161,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  reported a Q4 net loss Thursday of $1.27 per diluted share, narrower than a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $1.33.Collaboration revenue for the quarter ended Dec. 31 was $12.9 million, compared with a revenue loss of $1.9 million a year earlier.Analysts surveyed by FactSet expected $8.6 million.The company said it had cash, cash equivalents and marketable securities of $861.7 million as of Dec. 31, which is expected to fund operations into H1 2027.Intellia shares were rising past 5% in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU1861558580.USD","NTLA","BK4139","BK4556","LU1861559042.SGD","BK4585","BK4535"],"gpt_icon":0},{"id":"2514250809","title":"Intellia Therapeutics Q4 Net Income USD -128.898 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514250809","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514250809?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:41","pubTimestamp":1740660086,"startTime":"0","endTime":"0","summary":"Feb 27 (Reuters) - Intellia Therapeutics Q4 operating expenses USD 149.321 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-FEB-202512:24:39.433 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nRSD4KCjpb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","LU1861559042.SGD","BK4535","LU1861558580.USD","NTLA","BK4556","BK4585"],"gpt_icon":0},{"id":"2514089806","title":"Intellia Therapeutics Q4 Basic EPS USD -1.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2514089806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514089806?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:30","pubTimestamp":1740659401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX358469:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","BK4535","LU1861559042.SGD","LU1861558580.USD","BK4585","NTLA","BK4588"],"gpt_icon":0},{"id":"2514099608","title":"Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099608","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099608?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:30","pubTimestamp":1740659400,"startTime":"0","endTime":"0","summary":"Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033745/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","IE00B64QTZ34.USD","BK4585","LU0106261612.USD","BK4588","LU1861558580.USD","LU0012050646.USD","LU1169589451.USD","IE00BLDYK493.USD","LU2065732104.USD","HAE","BK4097","CRSP","LU0205193047.USD","LU1861559042.SGD","PRGS","LU1169590202.USD","BK4535","BK4198","NTLA","BK4139","BK4556"],"gpt_icon":1},{"id":"2514850719","title":"Beam Therapeutics Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514850719","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514850719?lang=en_us&edition=fundamental","pubTime":"2025-02-27 00:51","pubTimestamp":1740588660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 11:51 ET (16:51 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4556","LENZ","BK4207","BK4139","BK4585","BK4588","BEAM","BK4535"],"gpt_icon":0},{"id":"2514852178","title":"Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2514852178","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514852178?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:19","pubTimestamp":1740579540,"startTime":"0","endTime":"0","summary":"It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus.bluebird bio’s BLUE shares plunged after the company announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle and SK Capital Partners, LP.Gilead Sciences, Inc. GILD announced that the European Medicines Agency  has validated the company’s marketing authorization application and EU-Medicines for all applications for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Gilead is seeking approval for lenacapavir for the prevention of HIV as pre-exposure prophylaxis .Both these applications are being assessed under an accelerated assessment review timeline as the EMA’s Committee for Medicinal Products for Human Use  determined that twice-yearly lenacapavir for HIV prevention is a product of major interest for public health and therapeutic innovation.BioMarin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-blue-down-141900146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BLUE","LU0289739699.SGD","IE00BZ1G4Q59.USD","BK4139","LU0234570918.USD","LU1066053197.SGD","LU1430594728.SGD","IE00B3T34201.USD","CHMP","LU0320765992.SGD","BK4588","LU2468319806.SGD","BMRN","GILD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4583","BK4578","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4550","BK4585","LU0889565916.HKD","BK4568","TRDA","IE00B19Z3581.USD","BK4556","BK4087","LU0058720904.USD","LU0109394709.USD","BK4532","LU1585245621.USD","LU1066051498.USD","BK4566","LU1571399168.USD","LU1839511570.USD","IE00BKVL7J92.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2514718831","title":"Beam Therapeutics: Anticipated Growth Driven by BEAM-302 and SCD Franchise Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514718831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514718831?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:18","pubTimestamp":1740572308,"startTime":"0","endTime":"0","summary":"BMO Capital analyst Kostas Biliouris has maintained their bullish stance on BEAM stock, giving a Buy rating yesterday. Kostas Biliouris’s rating is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/beam-therapeutics-anticipated-growth-driven-by-beam-302-and-scd-franchise-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/beam-therapeutics-anticipated-growth-driven-by-beam-302-and-scd-franchise-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4585","PRGS","BEAM","LU2065732104.USD","SCD","BK4505","BK4588","BK4139","BK4097","BK4535"],"gpt_icon":0},{"id":"2514887463","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS) and Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887463?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:20","pubTimestamp":1740565252,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Addus Homecare (ADUS – Research Report) and Beam T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-addus-homecare-adus-and-beam-therapeutics-beam?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-addus-homecare-adus-and-beam-therapeutics-beam?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","HCSG","BK4535","IE00BN0W2T93.GBP","BK4585","BK4588","BK4196","BK4139","BK4505","BK4137","IE00BN0W2V16.EUR","ADUS","IE00BN0W2W23.USD","BEAM"],"gpt_icon":0},{"id":"2514887477","title":"Beam Therapeutics (BEAM) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887477?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:20","pubTimestamp":1740565218,"startTime":"0","endTime":"0","summary":"In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-hold-from-barclays-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-hold-from-barclays-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4556","BK4139","BK4585","BEAM","BK4535","BK4588"],"gpt_icon":0},{"id":"2514009390","title":"Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009390?lang=en_us&edition=fundamental","pubTime":"2025-02-26 15:01","pubTimestamp":1740553294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH0KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4505","BK4139","BK4585","BK4556","BK4588","BEAM"],"gpt_icon":0},{"id":"2514074303","title":"Beam Therapeutics Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514074303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514074303?lang=en_us&edition=fundamental","pubTime":"2025-02-26 12:21","pubTimestamp":1740543708,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. ( ($BEAM) ) has released its Q4 earnings. Here is a breakdown of the information Beam Therapeutics, Inc. presented to its i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4097","LENZ","BK4505","LU2065732104.USD","BK4139","BK4585","BK4556","PRGS","BK4588","BEAM"],"gpt_icon":0},{"id":"2514809344","title":"Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2514809344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514809344?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLXBC8901:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BEAM","BK4505","BK4556","BK4139","BK4585","BK4588"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":62}]}}